Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
December 03 2024 - 7:00AM
Business Wire
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF)
(“Satellos”), a public biotech company developing new
small molecule therapeutic approaches to improve the treatment of
muscle diseases and disorders, announced today that Frank Gleeson,
Co-founder and CEO will participate in Oppenheimer’s Movers in Rare
Disease Summit taking place in New York City on December 12,
2024.
Oppenheimer’s Movers in Rare Disease Summit Title:
Polypharmacy in DMD and Neuromuscular Disease Format:
Fireside Chat Date: December 12, 2024 Time: 9:50AM
ET
Additionally, management will be available for one-on-one
meetings with registered attendees at the summit.
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company dedicated
to developing life-improving medicines to treat degenerative muscle
diseases. Satellos has invented SAT-3247 as a first-of-its-kind,
orally administered small molecule drug designed to restore
skeletal muscle regeneration initially in Duchenne muscular
dystrophy (DMD). Satellos has generated a significant body of
preclinical evidence in DMD to support that correcting muscle stem
cell polarity with SAT-3247 has the potential to restore skeletal
muscle regeneration to repair and strengthen muscle that has been
damaged. The Company’s lead drug candidate SAT-3247 is currently in
clinical development as a potential disease-modifying treatment
DMD. Additionally, Satellos is leveraging its breakthrough research
in muscle stem cell polarity and proprietary discovery platform
MyoReGenX™, to identify degenerative muscle diseases where deficits
in muscle regeneration occur that are amenable to therapeutic
intervention for future clinical development. For more information,
visit www.satellos.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241203768538/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Jessica Yingling, Ph.D., jessica@litldog.com,
+1.858.344.8091
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Nov 2024 to Dec 2024
Satellos Bioscience (TSX:MSCL)
Historical Stock Chart
From Dec 2023 to Dec 2024
